Volume 15, Issue 1, Pages (January 2012)

Slides:

Advertisements

Similar presentations

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)— Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication.

Advertisements

A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence Susan Ross, MD, FRCPC, Ebony Samuels, PhD, Kerry Gairy, MSc, Sheikh Iqbal, MD,

Program-Specific Cost-Effectiveness Analysis: Breast Cancer Screening Policies for a Safety-Net Program Joy Melnikow, MD, MPH, Daniel J. Tancredi, PhD,

Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical.

Cost-Effectiveness of Sensor-Augmented Pump Therapy in Adults with Type 1 Diabetes in the United States Shital Kamble, PhD, Kevin A. Schulman, MD, Shelby.

Cost-Effectiveness of Partially Hydrolyzed Whey Protein Formula in the Primary Prevention of Atopic Dermatitis in At-Risk Urban Filipino Infants Abhijeet.

Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis Beth Woods,

Volume 14, Issue 8, Pages (December 2011)

Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual.

Volume 18, Issue 5, Pages (July 2015)

Mapping the COPD Assessment Test onto EQ-5D

Volume 15, Issue 2, Pages (March 2012)

Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-

Volume 17, Issue 2, Pages (March 2014)

Volume 14, Issue 1, Pages (January 2011)

Volume 15, Issue 1, Pages S20-S28 (January 2012)

Volume 14, Issue 4, Pages (June 2011)

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Volume 17, Issue 8, Pages (December 2014)

Volume 14, Issue 4, Pages (June 2011)

Volume 15, Issue 6, Pages (September 2012)

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Klára Kruntorádová, MSc, Jiří Klimeš,

Multidomain Patient-Reported Outcomes of Irritable Bowel Syndrome: Exploring Person-Centered Perspectives to Better Understand Symptom Severity Scores

Volume 19, Issue 5, Pages (July 2016)

Volume 15, Issue 2, Pages (March 2012)

Volume 17, Issue 2, Pages (March 2014)

Examining the Value of Menopausal Symptom Relief Among US Women

Volume 17, Issue 2, Pages (March 2014)

Volume 19, Issue 6, Pages (September 2016)

Value in Health Regional Issues

Value in Health Regional Issues

The Development of the Romanian Scorecard HTA System

Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt

Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future? Emmanuel Ankrah Odame, MBCHB, MPH Value in.

The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan Kaoru Yamabe, MSc, Puneet K. Singhal,

Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil Ronaldo K.

The Process of Privatization of Health Care Provision in Poland

Boxiong Tang, MD, PhD, Eran Harary, MD, Ricky Kurzman, MSc, Joaquín F

Ernest Attuquaye Quaye, BPharm, MPH, Edward O

Cost-Effectiveness of Routine Screening for Cardiac Toxicity in Patients Treated with Imatinib in Brazil Eduardo Gehling Bertoldi, MD, MSc, Milena S.

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Klára Kruntorádová, MSc, Jiří Klimeš,

Radiology Services Costs and Utilization Patterns Estimates in Southeastern Europe—A Retrospective Analysis from Serbia Mihajlo Jakovljević, MD, PhD,

Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,

Economic Evaluation of Bariatric Surgery in Mexico Using Discrete Event Simulation Olivo Omar Zanela, MSc, Hermilo Arturo Cabra, MSc, Guillermo Meléndez,

Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,

Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD

Burden of Disease and Economic Impact of Dengue and Severe Dengue in Colombia, 2011 Carlos Castañeda-Orjuela, MD, MSc, Hernando Díaz, PhD, Nelson Alvis-Guzman,

Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD

Omneya Mohamed, PhD, David H. Kreling, PhD

Value in Health Regional Issues

Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy? Fei-Li.

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project Kyriakos Souliotis, PhD,

Economic Burden of Individual Suffering from Atrial Fibrillation–Related Stroke in China Shanlian Hu, MSc, Lin Zhan, MSc, Bao Liu, MD, PhD, Yue Gao, MD,

The Methodological Challenges for the Estimation of Quality of Life in Children for Use in Economic Evaluation in Low-Income Countries Travor Mabugu,

Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters? Chun-Ru Chien, MD, PhD, Ya-Chen Tina.

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan Yoshie Onishi, MS,

Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD

Guidance Document: Global Pharmacoeconomic Model Adaption Strategies

Value in Health Regional Issues

Dossier System as a Practical Tool for Compiling Reimbursement Lists

Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico

Social Cost of Substance Abuse in Russia

Economic Evaluation of Four Drug Administration Systems in Intensive Care Units in Colombia Diego Rosselli, MD, MSc, Juan David Rueda, MD, María Daniela.

Victoria I. Ignatyeva, MPH, Johan L

Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.

Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD

Presentation transcript:

Volume 15, Issue 1, Pages 94-105 (January 2012) Reviewing the Cost-Effectiveness of Endocrine Early Breast Cancer Therapies: Influence of Differences in Modeling Methods on Outcomes Gerardus W.J. Frederix, MSc, Johan L. Severens, PhD, Anke M. Hövels, PhD, Jan A.M. Raaijmakers, PhD, Jan H.M. Schellens, MD, PhD Value in Health Volume 15, Issue 1, Pages 94-105 (January 2012) DOI: 10.1016/j.jval.2011.08.003 Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Decision tree of included and excluded studies, with reasons for exclusions. CE, cost-effectiveness; CU, cost utility; NHSEED, National Health Service Economic Evaluation Database. Value in Health 2012 15, 94-105DOI: (10.1016/j.jval.2011.08.003) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Overview of time schedules and treatment duration of clinical trials applied in the pharmacoeconomic evaluation of endocrine therapies in early breast cancer (ATAC [32], Intergroup Exemestane Study [33], BIG 1-98 [34], and MA-17 [42]. Value in Health 2012 15, 94-105DOI: (10.1016/j.jval.2011.08.003) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions